Immune Response News and Research

RSS

Two microbial metabolites compete to control the cells' protein building machinery

The microbiome-the trillions of bacteria, viruses, and fungi that live quietly in our body-plays a crucial role in shaping human health by providing a variety of micronutrients necessary for vital functions.

30 Oct 2025

Leveraging the power of T cells for more effective and durable cancer immunotherapies

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main goal in immunotherapy.

24 Oct 2025

Antibody discovery could provide new treatment options for aggressive breast cancers

A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

23 Oct 2025

Disruption of glial circadian rhythms linked to Alzheimer's disease progression

Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased napping during the day are early indicators of disease onset, while sundowning, or confusion later in the day, is typical for later stages of the disease.

23 Oct 2025

New study solves lung transplant rejection mystery

More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery.

22 Oct 2025

$VT3989 shows promising antitumor activity in refractory mesothelioma patients$

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Night shift work may raise risk of irritable bowel syndrome

The study indicates that night shift work increases irritable bowel syndrome risk, particularly among those with obesity, due to circadian rhythm disturbances.

22 Oct 2025

Researchers develop a novel approach to monitor CD8⁺ T cell activity over time

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

21 Oct 2025

CRATERs identified as key sites for T cell-mediated tumor destruction

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing. These craters could serve as good markers for immunotherapy success.

17 Oct 2025

Researchers uncover TRAT1's central role in T helper cell function

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the immune system: the protein molecule TRAT1 (T Cell Receptor Associated Transmembrane Adaptor 1) plays a central role in how so-called T helper cells (a specialised subgroup of immune cells) distinguish between attack and self-control - an important mechanism for restraining inflammation and preventing autoimmune diseases. The findings have recently been published in the journal Cell Communication and Signaling.

16 Oct 2025

CRISPR therapy shows promise against influenza in human lung chips

The Influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

15 Oct 2025

SGLT-2 inhibitors offer protection against autoimmune conditions

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, compared with another group of diabetes drugs called sulfonylureas, finds a study from South Korea published by The BMJ today.

15 Oct 2025

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025